Complete resolution of febrile ulceronecrotic Mucha-Habermann disease following infliximab therapy

J Dtsch Dermatol Ges. 2016 Feb;14(2):184-6. doi: 10.1111/ddg.12742. Epub 2016 Jan 20.

Authors

Alexander Kreuter¹, Sarah Knispel¹, Ulrike Wieland², Frank Oellig³, Christian Tigges¹

Affiliations

¹ Department of Dermatology, Venereology, and Allergology, HELIOS St. Elisabeth Hospital, Oberhausen. Germany.
² Institute for Virology, National Reference Center for Papilloma- und Polyomaviruses, University of Cologne, Cologne, Germany.
³ Pathological Institute Rhein-Ruhr, Mülheim an der Ruhr, Germany.

PMID: 26790133
DOI: 10.1111/ddg.12742

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Inflammatory Agents / administration & dosage
Herpes Simplex / drug therapy*
Herpes Simplex / pathology*
Humans
Infliximab / administration & dosage*
Male
Pityriasis Lichenoides / drug therapy*
Pityriasis Lichenoides / pathology*
Skin / drug effects
Skin / pathology*
Treatment Outcome

Substances

Anti-Inflammatory Agents
Infliximab

Supplementary concepts

Febrile Ulceronecrotic Mucha-Habermann disease